

Eugenia Negredo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/142567/publications.pdf>

Version: 2024-02-01

159
papers

5,535
citations

70961

41
h-index

95083

68
g-index

169
all docs

169
docs citations

169
times ranked

5711
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut Microbiota Linked to Sexual Preference and HIV Infection. <i>EBioMedicine</i> , 2016, 5, 135-146.	2.7	328
2	Prospective Randomized Two-Arm Controlled Study To Determine the Efficacy of a Specific Intervention To Improve Long-Term Adherence to Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 25, 221-228.	0.9	203
3	Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. <i>Aids</i> , 2000, 14, 397-403.	1.0	189
4	Virological, Immunological, and Clinical Impact of Switching from Protease Inhibitors to Nevirapine or to Efavirenz in Patients with Human Immunodeficiency Virus Infection and Long-Lasting Viral Suppression. <i>Clinical Infectious Diseases</i> , 2002, 34, 504-510.	2.9	170
5	Long-Term Neuropsychiatric Disorders on Efavirenz-Based Approaches. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 38, 560-565.	0.9	151
6	Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor-Experienced Patients With HIV-Associated Lipodystrophy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 27, 229-236.	0.9	143
7	High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. <i>Aids</i> , 2010, 24, 2827-2833.	1.0	140
8	Quality of Life, Emotional Status, and Adherence of HIV-Infected Patients Treated With Efavirenz Versus Protease Inhibitor-Containing Regimens. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 29, 244-253.	0.9	134
9	Nadir CD4 T Cell Count as Predictor and High CD4 T Cell Intrinsic Apoptosis as Final Mechanism of Poor CD4 T Cell Recovery in Virologically Suppressed HIV-Infected Patients: Clinical Implications. <i>Clinical Infectious Diseases</i> , 2010, 50, 1300-1308.	2.9	133
10	HIV and Syphilis: When to Perform a Lumbar Puncture. <i>Sexually Transmitted Diseases</i> , 2007, 34, 141-144.	0.8	124
11	CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. <i>Aids</i> , 2010, 24, 959-968.	1.0	114
12	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naïve adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2018, 5, e211-e220.	2.1	108
13	Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. <i>Aids</i> , 2004, 18, 459-463.	1.0	103
14	Measurement of Intracellular Didanosine and Tenofovir Phosphorylated Metabolites and Possible Interaction of the Two Drugs in Human Immunodeficiency Virus-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1907-1914.	1.4	101
15	The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2015, 61, 403-408.	2.9	100
16	Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-Analysis. <i>PLoS ONE</i> , 2011, 6, e22003.	1.1	93
17	Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. <i>Aids</i> , 2002, 16, 1383-1389.	1.0	92
18	Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome. <i>Journal of Translational Medicine</i> , 2013, 11, 68.	1.8	92

#	ARTICLE	IF	CITATIONS
19	Nadir CD4 Cell Count Predicts Neurocognitive Impairment in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1301-1307.	0.5	87
20	Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. <i>Lancet HIV</i> , 2018, 5, e23-e34.	2.1	83
21	Immunodiscordant responses to HAART – mechanisms and consequences. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 1135-1149.	1.3	79
22	Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. <i>Aids</i> , 2005, 19, 569-575.	1.0	75
23	A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients. <i>Aids</i> , 2018, 32, 1431-1442.	1.0	72
24	Pilot Pharmacokinetic Study of Human Immunodeficiency Virus-Infected Patients Receiving Tenofovir Disoproxil Fumarate (TDF): Investigation of Systemic and Intracellular Interactions between TDF and Abacavir, Lamivudine, or Lopinavir-Ritonavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1937-1943.	1.4	68
25	Role of Structured Treatment Interruption before a Drug Salvage Antiretroviral Regimen: The Retrogene Study. <i>Journal of Infectious Diseases</i> , 2003, 188, 977-985.	1.9	66
26	Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor-Experienced Patients With HIV-Associated Lipodystrophy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 27, 229-236.	0.9	63
27	Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons. <i>Clinical Infectious Diseases</i> , 2013, 57, 112-121.	2.9	56
28	Aging in HIV-Infected Subjects: A New Scenario and a New View. <i>BioMed Research International</i> , 2017, 2017, 1-9.	0.9	56
29	Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection. <i>Mucosal Immunology</i> , 2019, 12, 232-246.	2.7	56
30	Evaluation of the anti-HIV activity of statins. <i>Aids</i> , 2005, 19, 1697-1700.	1.0	53
31	Impact of Nevirapine on Lipid Metabolism. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, S79-S84.	0.9	50
32	Specificity enhancement with LC-positive ESI-MS/MS for the measurement of nucleotides: application to the quantitative determination of carbonyl triphosphate, lamivudine triphosphate and tenofovir diphosphate in human peripheral blood mononuclear cells. <i>Journal of Mass Spectrometry</i> , 2008, 43, 224-233.	0.7	50
33	Reconstructive Treatment for Antiretroviral-Associated Facial Lipoatrophy: A Prospective Study Comparing Autologous Fat and Synthetic Substances. <i>AIDS Patient Care and STDs</i> , 2006, 20, 829-837.	1.1	48
34	Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1965-1971.	1.3	48
35	Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. <i>Aids</i> , 2004, 18, 819-821.	1.0	46
36	Lopinavir/Ritonavir Plus Nevirapine as a Nucleoside-Sparing Approach in Antiretroviral-Experienced Patients (NEKA Study). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 47-52.	0.9	45

#	ARTICLE	IF	CITATIONS
37	Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. <i>Aids</i> , 2005, 19, 343-5.	1.0	45
38	Safety and Efficacy of Once-Daily Didanosine, Tenofovir and Nevirapine as a Simplification Antiretroviral Approach. <i>Antiviral Therapy</i> , 2004, 9, 335-342.	0.6	45
39	Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery. <i>Aids</i> , 2012, 26, 2285-2293.	1.0	44
40	Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3368-3371.	1.3	43
41	Alternation of Antiretroviral Drug Regimens for HIV Infection. <i>Annals of Internal Medicine</i> , 2003, 139, 81.	2.0	42
42	Simultaneous Population Pharmacokinetic Model for Lopinavir and Ritonavir in HIV-Infected Adults. <i>Clinical Pharmacokinetics</i> , 2008, 47, 681-692.	1.6	42
43	Assessing Self-Reported Adherence to HIV Therapy by Questionnaire: The SERAD (Self-Reported) Tj ETQq1 1 0.784314 rgBT /Overlock 0,5 41	0.5	41
44	Improvement of Mitochondrial Toxicity in Patients Receiving a Nucleoside Reverse Transcriptase Inhibitor Sparing Strategy: Results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). <i>Clinical Infectious Diseases</i> , 2009, 49, 892-900.	2.9	41
45	High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. <i>Antiviral Research</i> , 2012, 96, 65-69.	1.9	39
46	COVIDApp as an Innovative Strategy for the Management and Follow-Up of COVID-19 Cases in Long-Term Care Facilities in Catalonia: Implementation Study. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e21163.	1.2	39
47	Monitoring Atazanavir Concentrations With Boosted or Unboosted Regimens in HIV-Infected Patients in Routine Clinical Practice. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 648-651.	1.0	36
48	Hypertension Is a Key Feature of the Metabolic Syndrome in Subjects Aging with HIV. <i>Current Hypertension Reports</i> , 2016, 18, 46.	1.5	36
49	High Prevalence of Sarcopenia in HIV-Infected Individuals. <i>BioMed Research International</i> , 2018, 2018, 1-5.	0.9	36
50	Benefits and concerns of simplification strategies in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 235-242.	1.3	35
51	Herb-Drug Interaction between Echinacea purpurea and Darunavir-Ritonavir in HIV-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 326-330.	1.4	35
52	Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery. <i>Journal of Translational Medicine</i> , 2015, 13, 230.	1.8	33
53	Pulse Wave Velocity as Index of Arterial Stiffness in HIV-Infected Patients Compared With a Healthy Population. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 50-56.	0.9	31
54	Peak Bone Mass in Young HIV-Infected Patients Compared With Healthy Controls. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 207-212.	0.9	30

#	ARTICLE	IF	CITATIONS
55	The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy. <i>Aids</i> , 2006, 20, 619-621.	1.0	28
56	HIV-1 Infection in Subjects Older than 70: A Multicenter Cross-Sectional Assessment in Catalonia, Spain. <i>Current HIV Research</i> , 2009, 7, 597-600.	0.2	28
57	The Changing Face of HIV/AIDS in Treated Patients. <i>Current HIV Research</i> , 2009, 7, 365-377.	0.2	28
58	Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2358-2362.	1.3	28
59	Four-Year Safety with Polyacrylamide Hydrogel to Correct Antiretroviral-Related Facial Lipoatrophy. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 451-455.	0.5	27
60	Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals. <i>PLoS ONE</i> , 2014, 9, e114142.	1.1	27
61	Longitudinal Study on Mitochondrial Effects of Didanosine/Tenofovir Combination. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 33-39.	0.5	26
62	Genetic and Functional Mitochondrial Assessment of HIV-Infected Patients Developing HAART-Related Hyperlactatemia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 443-451.	0.9	26
63	Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort. <i>Antiviral Research</i> , 2010, 88, 347-354.	1.9	26
64	A Brief and Feasible Paper-Based Method to Screen for Neurocognitive Impairment in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 585-592.	0.9	26
65	Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2015, 60, 811-820.	2.9	26
66	Compromised Immunologic Recovery in Treatment-Experienced Patients with HIV Infection Receiving Both Tenofovir Disoproxil Fumarate and Didanosine in the TORO Studies. <i>Clinical Infectious Diseases</i> , 2005, 41, 901-905.	2.9	25
67	Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1382-1387.	1.3	25
68	Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2104-2107.	1.3	25
69	Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 436-439.	1.3	24
70	Herb-Drug Interaction between <i>Echinacea purpurea</i> and Etravirine in HIV-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5328-5331.	1.4	24
71	Effect of Milk Thistle on the Pharmacokinetics of Darunavir-Ritonavir in HIV-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2837-2841.	1.4	23
72	In Vivo, Non-Invasive Characterization of Human Bone by Hybrid Broadband (600-1200 nm) Diffuse Optical and Correlation Spectroscopies. <i>PLoS ONE</i> , 2016, 11, e0168426.	1.1	23

#	ARTICLE	IF	CITATIONS
73	Low-Density Lipoprotein Size and Lipoprotein-Associated Phospholipase A2 in HIV-Infected Patients Switching to Abacavir or Tenofovir. <i>Antiviral Therapy</i> , 2011, 16, 459-468.	0.6	22
74	Antiretroviral Simplification with Darunavir/Ritonavir Monotherapy in Routine Clinical Practice: Safety, Effectiveness, and Impact on Lipid Profile. <i>PLoS ONE</i> , 2012, 7, e37442.	1.1	21
75	Lopinavir/Ritonavir Pharmacokinetics in HIV and Hepatitis C Virus Co-Infected Patients without Liver Function Impairment. <i>Clinical Pharmacokinetics</i> , 2007, 46, 85-92.	1.6	19
76	Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 784-792.	1.3	19
77	Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 390-396.	0.9	19
78	Classification Models for Neurocognitive Impairment in HIV Infection Based on Demographic and Clinical Variables. <i>PLoS ONE</i> , 2014, 9, e107625.	1.1	19
79	Clinical and Emotional Factors Related to Erectile Dysfunction in HIV-Infected Men. <i>American Journal of Men's Health</i> , 2017, 11, 647-653.	0.7	19
80	A retrospective cohort study of risk factors for mortality among nursing homes exposed to COVID-19 in Spain. <i>Nature Aging</i> , 2021, 1, 579-584.	5.3	19
81	Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 70, 1130-8.	1.3	18
82	Pharmacologic approaches to the prevention and management of low bone mineral density in HIV-infected patients. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 351-357.	1.5	18
83	The Aging Imageomics Study: rationale, design and baseline characteristics of the study population. <i>Mechanisms of Ageing and Development</i> , 2020, 189, 111257.	2.2	18
84	Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4+ T-cell immune recovery. <i>PLoS ONE</i> , 2017, 12, e0184433.	1.1	17
85	A Specific Mobile Health Application for Older HIV-Infected Patients: Usability and Patient's Satisfaction. <i>Telemedicine Journal and E-Health</i> , 2021, 27, 432-440.	1.6	17
86	Simplification Therapy with Once-Daily Didanosine, Tenofovir and Efavirenz in HIV-1-Infected Adults with Viral Suppression Receiving a More Complex Antiretroviral Regimen: Final Results of the EFADITE Trial. <i>Antiviral Therapy</i> , 2005, 10, 825-832.	0.6	17
87	High Prevalence of Signs of Renal Damage Despite Normal Renal Function in a Cohort of HIV-Infected Patients: Evaluation of Associated Factors. <i>AIDS Patient Care and STDs</i> , 2014, 28, 524-529.	1.1	16
88	Time of Progression to Osteopenia/Osteoporosis in Chronically HIV-Infected Patients: Screening DXA Scan. <i>PLoS ONE</i> , 2012, 7, e46031.	1.1	16
89	Influence of Prior Structured Treatment Interruptions on the Length of Time without Antiretroviral Treatment in Chronically HIV-Infected Subjects. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 1283-1288.	0.5	15
90	Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?. <i>Journal of NeuroVirology</i> , 2010, 16, 208-218.	1.0	13

#	ARTICLE	IF	CITATIONS
91	Assessing main death pathways in T lymphocytes from HIV infected individuals. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2013, 83A, 648-658.	1.1	13
92	Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial. <i>Lancet HIV</i> , 2021, 8, e463-e473.	2.1	13
93	Long-Term Effectiveness and Safety Outcomes in HIV-1-Infected Patients After a Median Time of 6 Years on Nevirapine. <i>Current HIV Research</i> , 2009, 7, 526-532.	0.2	12
94	Impact of Switching from Lopinavir/Ritonavir to Atazanavir/Ritonavir on Body Fat Redistribution in Virologically Suppressed HIV-Infected Adults. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 1061-1065.	0.5	12
95	Preserved immune functionality and high CMV-specific T-cell responses in HIV-infected individuals with poor CD4+ T-cell immune recovery. <i>Scientific Reports</i> , 2017, 7, 11711.	1.6	12
96	Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 400-404.	1.3	11
97	Prevalence, evolution, and related risk factors of kidney disease among Spanish HIV-infected individuals. <i>Medicine (United States)</i> , 2017, 96, e7421.	0.4	11
98	Memory B cell dysregulation in HIV-1-infected individuals. <i>Aids</i> , 2018, 32, 149-160.	1.0	11
99	Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor-Containing Regimen. Etraswitch Study. <i>PLoS ONE</i> , 2014, 9, e84676.	1.1	11
100	Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. <i>Antiviral Therapy</i> , 2004, 9, 335-42.	0.6	11
101	Low Levels of Adherence to Antiretroviral Therapy in HIV-1-Infected Women with Menstrual Disorders. <i>AIDS Patient Care and STDs</i> , 2009, 23, 463-468.	1.1	10
102	Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients. <i>Antiviral Therapy</i> , 2010, 15, 219-225.	0.6	10
103	Emotional Impact of Premature Aging Symptoms in Long-Term Treated HIV-Infected Subjects. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, e5-e8.	0.9	10
104	Ten-Year Safety with Polyacrylamide Gel Used to Correct Facial Lipoatrophy in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 817-821.	0.5	10
105	Antiretroviral therapy suppressed participants with low CD4+ T-cell counts segregate according to opposite immunological phenotypes. <i>Aids</i> , 2016, 30, 2275-2287.	1.0	10
106	Impact of HIV infection on aging and immune status. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 719-731.	2.0	10
107	Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 72, dkw504.	1.3	9
108	Increased cholesterol absorption rather than synthesis is involved in boosted protease inhibitor-associated hypercholesterolaemia. <i>Aids</i> , 2018, 32, 1309-1316.	1.0	9

#	ARTICLE	IF	CITATIONS
109	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 195-202.	0.3	9
110	Dolutegravir Monotherapy as Maintenance Strategy: A Meta-Analysis of Individual Participant Data From Randomized Controlled Trials. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	9
111	Alternation of Antiretroviral Drug Regimens for HIV Infection. Efficacy, Safety and Tolerability at Week 96 of the Swatch Study. <i>Antiviral Therapy</i> , 2004, 9, 889-893.	0.6	9
112	Therapeutic management of bone demineralization in the HIV-infected population. <i>Aids</i> , 2007, 21, 657-663.	1.0	8
113	A Randomized, Open-Label Study of a Nucleoside Analogue Reverse Transcriptase Inhibitor-Sparing Regimen in Antiretroviral-Naive HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 50, 335-337.	0.9	8
114	Immunological Function Restoration with Lopinavir/Ritonavir Versus Efavirenz Containing Regimens in HIV-Infected Patients: A Randomized Clinical Trial. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 425-433.	0.5	8
115	Potential prescribing issues among older HIV-infected subjects in a Mediterranean cohort: Does the current prevalence give cause for concern?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1310-1317.	1.1	8
116	Consensus document on the management of renal disease in HIV-infected patients. <i>Nefrología</i> , 2014, 34 Suppl 2, 1-81.	0.2	8
117	Time-resolved diffused optical characterization of key tissue constituents of human bony prominence locations. <i>Proceedings of SPIE</i> , 2015, , .	0.8	7
118	Association between polymorphisms in genes involved in lipid metabolism and immunological status in chronically HIV-infected patients. <i>Antiviral Research</i> , 2015, 114, 48-52.	1.9	7
119	Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity. <i>BioMed Research International</i> , 2016, 2016, 1-5.	0.9	7
120	Executive summary of the consensus document on osteoporosis in HIV-infected individuals. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 312-314.	0.3	7
121	Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 151-159.	0.3	7
122	Remote Health Monitoring in the Workplace for Early Detection of COVID-19 Cases during the COVID-19 Pandemic Using a Mobile Health Application: COVIDApp.. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 167.	1.2	7
123	Effect of Nevirapine on the Steady-State Trough Concentrations of Atazanavir in HIV-Infected Patients Receiving Atazanavir/Ritonavir. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 93-96.	1.0	6
124	Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC. <i>Journal of the International AIDS Society</i> , 2014, 17, 19550.	1.2	6
125	High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of Pls. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2452-2459.	1.3	6
126	Evaluation of Protease Inhibitors Containing Tubes for MS-Based Plasma Peptide Profiling Studies. <i>Journal of Clinical Laboratory Analysis</i> , 2014, 28, 364-367.	0.9	5

#	ARTICLE	IF	CITATIONS
127	Polymorphisms in <i>LPL</i> , <i>CETP</i> , and <i>HL</i> Protect HIV-Infected Patients from Atherogenic Dyslipidemia in an Allele-Dose-Dependent Manner. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 882-888.	0.5	5
128	Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients. <i>International Journal of STD and AIDS</i> , 2020, 31, 467-473.	0.5	5
129	Partial Immunological and Mitochondrial Recovery after Reducing Didanosine doses in Patients on Didanosine and Tenofovir-Based Regimens. <i>Antiviral Therapy</i> , 2008, 13, 231-240.	0.6	5
130	Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide. <i>Aids</i> , 2006, 20, 1896-1898.	1.0	4
131	Saquinavir/Ritonavir Monotherapy as a New Nucleoside-Sparing Maintenance Strategy in Long-Term Virologically Suppressed HIV-Infected Patients. <i>Current HIV Research</i> , 2010, 8, 467-470.	0.2	4
132	Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	4
133	Executive summary of the consensus document on metabolic disorders and cardiovascular risk in patients with HIV infection. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 41-47.	0.3	4
134	Management of bone mineral density in HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 845-852.	0.9	4
135	Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 929-934.	0.9	4
136	Factors associated with the number of drugs in darunavir/cobicistat regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 208-214.	1.3	4
137	Saquinavir exposure in HIV-infected patients with chronic viral hepatitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 992-997.	1.3	3
138	Similarly high prevalence of hypovitaminosis D in HIV-infected subjects with and without low bone mineral density. <i>Future Virology</i> , 2012, 7, 1127-1134.	0.9	3
139	TL1A DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1-Specific T Cell Responses. <i>Journal of Immunology</i> , 2020, 205, 3348-3357.	0.4	3
140	A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV. <i>PLoS ONE</i> , 2020, 15, e0238575.	1.1	3
141	Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens. <i>Antiviral Therapy</i> , 2008, 13, 231-40.	0.6	3
142	Long-term changes in bone mineral density after switching to a protease inhibitor monotherapy in HIV-infected subject. <i>New Microbiologica</i> , 2015, 38, 193-9.	0.1	3
143	Adipokines as New Biomarkers of Immune Recovery: Apelin Receptor, RBP4 and ZAG Are Related to CD4+ T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2202.	1.8	3
144	99m Tc-HMPAO SPET: a method to study visual loss in cryptococcal meningitis. <i>Acta Neurologica Scandinavica</i> , 2000, 102, 340-341.	1.0	2

#	ARTICLE	IF	CITATIONS
145	Efficacy and Safety of Ritonavir Dose Reduction Based on the Tipranavir Inhibitory Quotient in HIV-Infected Patients on Salvage Antiretroviral Therapy with Tipranavir/Ritonavir. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 1191-1196.	0.5	2
146	Mild Improvement in Mitochondrial Function After a 3-Year Antiretroviral Treatment Interruption Despite Persistent Impairment of Mitochondrial DNA Content. <i>Current HIV Research</i> , 2010, 8, 379-385.	0.2	2
147	Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner. <i>Journal of the International AIDS Society</i> , 2014, 17, 19557.	1.2	2
148	Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study. <i>Current HIV Research</i> , 2012, 10, 673-678.	0.2	2
149	Compromised Immunologic Recovery in Patients Receiving Tipranavir/Ritonavir Coadministered With Tenofovir and Didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resistant patients with Tipranavir (RESIST) Studies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 479-481.	0.9	1
150	Association between lipid genetic and immunological status in chronically HIV-infected patients. <i>Journal of the International AIDS Society</i> , 2014, 17, 19555.	1.2	1
151	Accentuated aging associated with HIV in a Mediterranean setting occurs mainly in persons aged > 70 years: a comparative cohort study (Over50 cohort). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, , 1-8.	0.6	1
152	Executive summary of the consensus document on the management of renal disease in HIV-infected patients. <i>Nefrologia</i> , 2014, 34, 768-88.	0.2	1
153	In vivo Time domain Broadband (600 -1200 nm) Diffuse Optical Characterization of Human Bone. , 2016, , .		0
154	A Multi-state Model for the Progression to Osteopenia and Osteoporosis Among HIV-Infected Patients. <i>Trends in Mathematics</i> , 2017, , 41-45.	0.1	0
155	Title is missing!. , 2020, 15, e0238575.		0
156	Title is missing!. , 2020, 15, e0238575.		0
157	Title is missing!. , 2020, 15, e0238575.		0
158	Title is missing!. , 2020, 15, e0238575.		0
159	Prevalence, progression, and management of advanced chronic kidney disease in a cohort of people living with HIV. <i>HIV Medicine</i> , 2022, , .	1.0	0